The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2014
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 14 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 14 Jan 2009.
- 30 Sep 2008 Actual patients number added 274 as reported by ClinicalTrials.gov.
- 30 Sep 2008 Planned end date (1 Sep 2003) added as reported by ClinicalTrials.gov.